General Cannabis (7A7) AI Stock Analysis

1 Followers

General Cannabis

(Stuttgart:7A7)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Operating profitability improvingEBIT turning positive in 2025 and sustained gross profit demonstrate material improvement in core unit economics. Durable margin recovery reduces cash burn risk, supports reinvestment or debt reduction, and increases the probability that the business can reach sustained profitability if revenue stabilizes.

Negative Factors

Negative shareholder equityNegative equity is a structural weakness that impairs financial flexibility and increases refinancing risk. It restricts access to conventional capital, can trigger covenant or counterparty issues, and typically forces dilutive issuances or costly debt solutions, affecting long-term solvency and strategy execution.

General Cannabis (7A7) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 1.84M
Dividend Yield: ―
Average Volume (3M): ―
Price to Earnings (P/E): -2.1
Beta (1Y): ―
Revenue Growth: ―
EPS Growth: ―
Country: Germany
Employees: 91
Sector: Healthcare
Sector Strength: 51
Industry: Drug Manufacturers - Specialty & Generic

General Cannabis Business Overview & Revenue Model

Company Description

Denver, Colorado-based Trees Corporation, founded in 2013, specializes in delivering products and services to both the regulated cannabis sector and general consumers throughout the United States. Its business activities are organized into distinct r...

General Cannabis Risk Analysis

General Cannabis disclosed 33 risk factors in its most recent earnings report. General Cannabis reported the most risks in the "Finance & Corporate" category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

0 New Risks

General Cannabis Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:7A7 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
AQST	47Neutral	$442.42M	-5.59	255.11%	―	12.54%	8.82%
IXHL	43Neutral	$25.21M	-1.76	-18.27%	―	-100.00%	95.90%
YCBD	43Neutral	$4.30M	-1.29	-34.25%	―	10.01%	95.01%
IMCC	37Underperform	$1.01M	-0.02	841.81%	―	-11.91%	-285.26%

* Healthcare Sector Average

Performance Comparison

DE:7A7 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:7A7	General Cannabis	0.10	0.00	0.00%
YCBD	Cbdmd INc	0.40	-0.34	-46.62%
AQST	Aquestive Therapeutics, Inc.	3.58	-1.72	-32.45%
IMCC	Im Cannabis Corp	0.57	-38.72	-98.54%
IXHL	Incannex Healthcare Limited Sponsored ADR	1.98	-8.74	-81.56%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

General Cannabis AI Stock Analysis